Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Estradiol (E2) Clear all

Conditions: Endometriosis
Interventions: elagolix, estradiol/norethindrone acetate (E2/NETA); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 37
States / cities: Anniston, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more

Conditions: Endometriosis
Interventions: Estradiol/Norethindrone Acetate, Placebo for Elagolix, Elagolix, Placebo for E2/NETA; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 681 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 188
States / cities: Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 140 more

Conditions: Contraception
Interventions: Relugolix Combination Therapy; Drug
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1,164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 109
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 89 more

Conditions: Menopause
Interventions: Estradiol withdrawal, Fragmented sleep; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Infertility
Interventions: AS900672-Enriched 50 microgram (mcg), AS900672-Enriched 100 mcg, AS900672-Enriched 150 mcg, Follitropin alfa 150 international unit (IU), Recombinant human chorionic gonadotropin (r-hCG); Drug
Lead sponsor: Merck KGaA, Darmstadt, Germany; Industry
Eligibility: 18 Years to 36 Years · Female only
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Menopausal Syndrome
Interventions: Estradiol (E2), Progesterone (P10) x90, Progesterone (P10) x10; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 45 Years to 55 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Heavy Menstrual Bleeding, Uterine Fibroid
Interventions: Relugolix, Estradiol/norethindrone acetate, Relugolix placebo, Estradiol/norethindrone acetate placebo; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 89
States / cities: Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more

Conditions: Uterine Leiomyoma, Uterine Fibroids
Interventions: Relugolix, Estradiol/norethindrone acetate, Placebo for relugolix, Placebo for E2/NETA; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 51 Years · Female only
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 72
States / cities: Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 61 more

Conditions: Cystic Fibrosis Related Bone Disease
Interventions: Estradiol 2 mg, Placebo; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy Women, Female Contraception
Interventions: NES-E2 CVR; Drug
Lead sponsor: Premier Research; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 385 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 11
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 7 more

Conditions: Fertility, Contraception
Interventions: Leuprolide acetate, Estrogen and Progesterone Replacement, Progestin; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Hypogonadotropic Hypogonadism
Interventions: Luveris® 75 IU, Luveris® 25 IU, Placebo, Recombinant human follicle stimulating hormone (r-hFSH), Recombinant human chorionic gonadotropin (r-hCG); Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Cognitive Impairment, Estrogen Deficiency, Menopause, Endothelial Dysfunction, Vascular Stiffness
Interventions: GnRHant + E2, GnRHant + Placebo; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Aurora, Colorado • Boulder, Colorado

Conditions: Healthy
Interventions: Relugolix/E2/NETA FDC, Relugolix, Erythromycin; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Premenopause, Healthy
Interventions: Estradiol steroid infusion, Progesterone steroid infusion; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Heavy Menstrual Bleeding, Uterine Fibroid
Interventions: Relugolix, Estradiol/norethindrone acetate; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 104
States / cities: Andalusia, Alabama • Birmingham, Alabama • Mobile, Alabama + 84 more

Conditions: Pulmonary Arterial Hypertension
Interventions: ESR-specific PET scan; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 13 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Heart Diseases, Left Ventricular Dysfunction
Interventions: Estradiol patch, Cetrotide, Fasting, Lower Body Negative Pressure; Drug · Other
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years to 30 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Endometriosis Related Pain
Interventions: Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 43
States / cities: Dothan, Alabama • Mesa, Arizona • Scottsdale, Arizona + 37 more

Conditions: Suicidal Ideation
Interventions: Transdermal Estradiol + Placebo, Oral Micronized Progesterone + Placebo, Placebos; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy
Interventions: IM Saline Placebo (0.25 ml), IM Estradiol valerate (2.5 mg), IM Saline Placebo (0.5 ml), IM Estradiol valerate (5.0 mg), Oral Micronized Progesterone, Oral Placebo, Ghrelin (0.3 ug/kg), Medroxyprogesterone - Acetate; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 50 Years to 80 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Heavy Menstrual Bleeding, Uterine Fibroid
Interventions: Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 76
States / cities: Andalusia, Alabama • Mobile, Alabama • Little Rock, Arkansas + 62 more

Conditions: Suppression of Ovulation
Interventions: 10 µg/day E2 with NES 200® µg/day, 20 µg/day E2 with NES 200® µg/day, 40 µg/day E2 with NES 200® µg/day; Drug
Lead sponsor: Kimberly Myer; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 197 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 8
States / cities: Baltimore, Maryland • New York, New York • Cincinnati, Ohio + 4 more

Conditions: Turner's Syndrome
Interventions: Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 138 Months to 13 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Chicago, Illinois • Baltimore, Maryland • Ann Arbor, Michigan

Search by objective public record fields.

A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy

Menopausal Sleep Fragmentation and Body Fat Gain

Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)

Early Menopause Hormone Treatment and Cognition

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Pilot E2 for Hypogonadal Women With CFBD

Study of Efficacy, Cycle Control, and Safety of a NES-E2 Contraceptive Vaginal Ring

Regulation of Cervical Mucus Secretion

Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])

Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function

A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men

Effect of Race on Gonadotropin Responses

LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH

Sex Differences in Myocardial Steatosis Induced Left Ventricular Dysfunction

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

Unique Effects of Perimenstrual Estradiol or Progesterone Supplementation on Perimenstrual Suicidality

Progesterone Amplifies Estrogen-stimulated Growth Hormone Secretion in Older Women

LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

A Dose-finding Study to Evaluate the Effect of a Contraceptive Vaginal Ring, Releasing Nestorone® and Estradiol, on Cycle Control, Ovulation Inhibition, and Pharmacokinetics in Normal Cycling Women

Initiating Transdermal Estradiol Therapy in Turner's Syndrome